SMC1A抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-2: HUVEC and Jurkat cell lysates, Primary antibody: P01817(SMC1A Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P01817(SMC1A Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P01817(SMC1A Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The SMC1A antibody targets the Structural Maintenance of Chromosomes 1A (SMC1A) protein, a key component of the cohesin complex critical for chromosome organization, DNA repair, and transcriptional regulation. SMC1A, along with other cohesin subunits, ensures sister chromatid cohesion during mitosis and meiosis, maintaining genomic stability. It also facilitates chromatin loop formation, influencing gene expression. Mutations in SMC1A are linked to Cornelia de Lange syndrome (CdLS), a developmental disorder, and certain cancers, underscoring its role in cellular health.

SMC1A antibodies are widely used in research to study cohesin dynamics, chromatin architecture, and disease mechanisms. They enable detection of SMC1A expression and localization via techniques like Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP). These tools help explore how cohesin dysfunction contributes to developmental defects or oncogenesis. Commercial SMC1A antibodies are typically validated in human or model organisms (e.g., mouse, zebrafish), supporting cross-species studies. Recent work also investigates SMC1A's post-translational modifications (e.g., phosphorylation during DNA damage responses), highlighting its regulatory complexity. As therapeutic targeting of cohesin gains interest in cancer, SMC1A antibodies remain vital for mechanistic and diagnostic research.